LIVN

LivaNova's stock has been impacted by several key events. The company reported strong first-quarter 2026 results, with net revenue increasing 14.3% year-over-year, and raised its full-year 2026 revenue and adjusted diluted EPS guidance. The company received FDA approval for its aura6000 System to treat moderate to severe obstructive sleep apnea. The OSPREY clinical study for obstructive sleep apnea demonstrated clinically significant responses and sustained improvements. Multiple analyst rating and price target adjustments occurred. VNS Therapy was assigned to a higher reimbursement category, increasing hospital outpatient payments. The diluted loss per share in Q1 2025 was significantly impacted by a SNIA environmental charge, which was not present in Q1 2026.